Karl D. Handelsman

Presidio Partners is a venture capital firm founded in the year 1989 by Thomas R. Baruch. The firm is headquartered in San Francisco, California.

Tularik, Inc. is engaged in the discovery and development of a broad range of novel and superior orally available medicines that act through the regulation of gene expression. Tularik's scientific platform is focused on three therapeutic areas: cancer, inflammation and metabolic disease. The company was founded in 1991 and is headquartered in South San Francisco, CA.

Whitehead Institute for Biomedical Research provides research and technology services. Its services include biomedical, genomics, and genetics for students. The company was founded by Edwin C. Whitehead in 1982 and is headquartered in Cambridge, MA.

Tetraphase Pharmaceuticals, Inc. is engaged in the development and production of novel tetracyclines for serious and life-threatening bacterial infections. It also develops eravacycline, a synthetic fluorocycline, as an intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of resistant and multi-drug-resistant infections. The company was founded on July 7, 2006 and is headquartered in Waltham, MA.

Intellikine LLC develops and manufactures small molecule drugs for the treatment of cancer. The company focused on the development of potent, selective small molecule inhibitors of the PI3K/Akt/mTOR pathway for the treatment of cancer, inflammation and autoimmune disorders. Intellikine was founded on May 2nd, 2007 and is headquartered in La Jolla, CA.

Neos Therapeutics, Inc is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Its products are Adzenys XR-ODT (amphetamine), Cotempla XR-ODT (methylphenidate), and Adzenys-ER (amphetamine) extended-release oral suspension, all for the treatment of ADHD, are the first three approved products using the Company's extended-release technology platform. The firm manufactures and markets its generic version of the branded product Tussionex, an extended-release oral suspension of hydrocodone and chlorpheniramine for the relief of cough and upper respiratory symptoms of a cold. The company was founded by Darlene R. Ryan on November 30, 1994 and is headquartered in Grand Prairie, TX.

Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA.

Velocity Pharmaceutical Development LLC develops pharmaceutical drugs. It identifies drug candidates, target markets and designing and managing outsourced clinical trials. The firm seeks to acquire promising drug candidates, generally within a year of their entering human clinical trials or after initial human clinical data have been generated. The company was founded by David Collier, Ed Schnipper, Jim Larrick and Andy Perlman in 2011 and is headquartered in South San Francisco, CA.

Roche Ventures is the venture investment division of the pharmaceutical company F. Hoffmann-La Roche Ltd., which is a subsidiary of Roche Holding AG (SWX:ROG). The group is headquartered in Basel with operations and affiliates worldwide, and is a world leader in pharmaceuticals and diagnostics. The firm was founded in 2002.